HELP revenueFY2026$5.10M
- FY YoY
- -14.9%
HELP revenue was $5.10M for fiscal 2026 (ended Mar 31, 2026), down 14.9% from fiscal 2025.
Helus Pharma Inc. (HELP) financials
For fiscal 2026 (ended Mar 31, 2026), Helus Pharma Inc. reported $5.10M of revenue and -$148.00M of net income.
- Revenue, FY2026
- $5.10M
- Revenue growth, YoY
- -14.9%
- Net income, FY2026
- -$148.00M
- Net margin
- -2901.9%
- EPS, diluted, FY2026
- -$4.25
- Cash
- $157.26M
- P/S
- 134.23
- Market cap
- $684.6M
FY2025FY2026
FY2025FY2026
HELP revenue and earnings growth
HELP net incomeFY2026-$148.00M
HELP net income was -$148.00M for fiscal 2026 (ended Mar 31, 2026), compared with -$81.61M in fiscal 2025.
HELP EPSFY2026-$4.25
HELP diluted EPS was -$4.25 for fiscal 2026 (ended Mar 31, 2026).
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Revenue | $5.10M | $5.99M |
| Research and development | $86.59M | $39.21M |
| Selling, general and admin | $45.14M | $32.63M |
| Income tax | $0 | $0 |
| Net income | -$148.00M | -$81.61M |
| EPS, basic | -$4.25 | -$4.04 |
| EPS, diluted | -$4.25 | -$4.04 |
| Diluted shares | 34.8M | 20.2M |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Cash and equivalents | $157.26M | $93.92M |
| Receivables | $5.03M | $4.09M |
| Current assets | $184.52M | $115.45M |
| Goodwill | $36.23M | $35.81M |
| Total assets | $251.17M | $179.90M |
| Current liabilities | $19.38M | $14.90M |
| Total liabilities | $19.38M | $14.90M |
| Shareholders' equity | $231.79M | $165.00M |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Operating cash flow | -$133.27M | -$72.33M |
| Investing cash flow | -$1.36M | -$1.40M |
| Financing cash flow | $198.24M | $14.10M |
| Stock-based compensation | $10.86M | $31.28M |
| Depreciation and amortization | $120.0K | $348.0K |
Key ratios
Source: XBRL data Helus Pharma Inc. files with the SEC, latest filing dated Jun 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
HELP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| HELP | $5.10M | -14.9% | -$148.00M | -2901.9% | $684.6M |
| CMPS | - | - | -$266.30M | - | $1.30B |
| NMRA | - | - | -$212.75M | - | $92.7M |
| AXSM | $865.27M | +54.2% | -$157.29M | -18.2% | $7.05B |
| ANRO | - | - | -$84.24M | - | $1.09B |
| RLMD | - | - | -$61.93M | - | $441.6M |
HELP FAQ
7 questionsWhat is HELP revenue?
Helus Pharma Inc. (HELP) reported $5.10M of revenue for fiscal 2026 (ended Mar 31, 2026). That is down 14.9% from the year before.Is HELP profitable?
No. Helus Pharma Inc. reported a net loss of $148.00M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does HELP have?
Helus Pharma Inc. reported $157.26M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is HELP revenue growing?
Helus Pharma Inc.'s revenue changed -14.9% in fiscal 2026, to $5.10M.What is HELP earnings per share?
Diluted earnings per share were -$4.25 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did HELP last report financial results?
The latest statements here come from Helus Pharma Inc.'s 40-F filed on Jun 29, 2026, covering the period ended Mar 31, 2026.Where does this HELP financial data come from?
Quantisnow builds these statements from the structured XBRL data Helus Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.